GlassScriptPhysician profile
Grace K Suh
NPI 1619033065
$8,064.96
in general payments reported to CMS, 2019-2025
10 companies · $3,009 in 2025
The $3,009 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $450 · 2021: $2,840 · 2022: $550 · 2023: $10.85 · 2024: $92.23 · 2025: $3,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,975 · Food and Beverage: $126 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,975.00 |
| Food and Beverage | $126.49 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,790.00 | 2021-2025 | Imfinzi |
| Daiichi Sankyo INC. | $1,200.00 | 2022-2025 | Vanflyta |
| Eli Lilly and Company | $1,100.66 | 2019 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Tempus Ai, INC | $92.23 | 2024 | |
| Azurity Pharmaceuticals, INC. | $34.26 | 2025 | Danziten |
| Pfizer INC. | $11.96 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.